CN1152880C - 羟氢吗啡酮、羟氢可待酮及其衍生物的制备方法 - Google Patents

羟氢吗啡酮、羟氢可待酮及其衍生物的制备方法 Download PDF

Info

Publication number
CN1152880C
CN1152880C CNB988088169A CN98808816A CN1152880C CN 1152880 C CN1152880 C CN 1152880C CN B988088169 A CNB988088169 A CN B988088169A CN 98808816 A CN98808816 A CN 98808816A CN 1152880 C CN1152880 C CN 1152880C
Authority
CN
China
Prior art keywords
carbon atom
acid
mmol
benzyl
normorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988088169A
Other languages
English (en)
Chinese (zh)
Other versions
CN1272845A (zh
Inventor
�����Ʊ���
黄宝善
G
A·柯瑞斯图督淕
陆岩松
嵇本一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penick Corp
Original Assignee
Penick Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25401603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1152880(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penick Corp filed Critical Penick Corp
Publication of CN1272845A publication Critical patent/CN1272845A/zh
Application granted granted Critical
Publication of CN1152880C publication Critical patent/CN1152880C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB988088169A 1997-07-11 1998-07-10 羟氢吗啡酮、羟氢可待酮及其衍生物的制备方法 Expired - Fee Related CN1152880C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/893,464 US5869669A (en) 1996-07-26 1997-07-11 Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US08/893,464 1997-07-11

Publications (2)

Publication Number Publication Date
CN1272845A CN1272845A (zh) 2000-11-08
CN1152880C true CN1152880C (zh) 2004-06-09

Family

ID=25401603

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988088169A Expired - Fee Related CN1152880C (zh) 1997-07-11 1998-07-10 羟氢吗啡酮、羟氢可待酮及其衍生物的制备方法

Country Status (19)

Country Link
US (7) US5869669A (https=)
EP (1) EP1000065B1 (https=)
JP (1) JP2001518444A (https=)
KR (1) KR100363486B1 (https=)
CN (1) CN1152880C (https=)
AT (1) ATE291023T1 (https=)
AU (1) AU740822B2 (https=)
CA (1) CA2296035C (https=)
DE (1) DE69829379D1 (https=)
HU (1) HUP0003918A3 (https=)
IL (1) IL133792A0 (https=)
IN (1) IN1998KO01500A (https=)
NO (1) NO20000111L (https=)
RU (1) RU2183636C2 (https=)
SK (1) SK102000A3 (https=)
TR (1) TR200000033T2 (https=)
TW (1) TW505648B (https=)
WO (1) WO1999002529A1 (https=)
ZA (1) ZA986144B (https=)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912347A (en) * 1996-09-30 1999-06-15 Mallinckrodt Inc. Process for preparing a morphinan derivative
WO2000066588A1 (en) * 1999-05-05 2000-11-09 The Government Of The United States Of America, Represented By The Secretary, Departmentof Health A Nd Human Services Direct c-14 oxidation of opioids
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
PL368732A1 (en) * 2001-08-23 2005-04-04 Akzo Nobel N.V. C-14 oxidation of morphine derivatives
JP3961796B2 (ja) * 2001-08-27 2007-08-22 ソニー株式会社 情報提供システム、情報処理装置および方法、情報提供装置および方法、記録媒体、並びにプログラム
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
RU2236412C2 (ru) * 2002-07-18 2004-09-20 Власов Михаил Иванович Способ получения производных морфинона, способ получения производных 14-гидроксиморфинона, и способ получения производных оксиморфона
RU2215742C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Способ получения сложных эфиров n-замещенных 14-гидроксиморфинанов
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
EP1562953B1 (en) * 2002-11-08 2009-09-30 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US6790959B1 (en) 2003-06-05 2004-09-14 Halsey Drug Company, Inc. Process for manufacturing thebaine
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
US7875718B2 (en) * 2003-09-22 2011-01-25 Johnson Matthey Public Limited Company Process for the synthesis of morphinane compounds and intermediates thereof
CA2539659C (en) 2003-09-22 2013-03-26 Johnson Matthey Public Limited Company Process for the synthesis of morphinane compounds and intermediates thereof
EA012905B1 (ru) 2004-02-06 2010-02-26 Еуро-Селтик С.А. Способы получения 3-о-защищенных морфинов и 3-о-защищенных морфинондиенолкарбоксилатов
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
SK286047B6 (sk) * 2004-04-13 2008-01-07 Zentiva, A. S. Spôsob prípravy derivátov 4,5alfa-epoxy-6-oxomorfínanu
US6946556B1 (en) * 2004-05-21 2005-09-20 Acura Pharmaceuticals, Inc. Preparation of opioid analgesics by a one-pot process
AU2005254933B2 (en) * 2004-06-08 2010-08-19 Mallinckrodt Inc. Extraction of alkaloids from opium
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
GB0421687D0 (en) * 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
WO2006084389A1 (de) * 2005-02-11 2006-08-17 Cilag Ltd. Verfahren zur reinigung von noroxymorphon-verbindungen
ME01594B (me) * 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
WO2006109671A1 (ja) * 2005-04-06 2006-10-19 Toray Industries, Inc. モルヒナン誘導体の結晶及びその製造法
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
ES2357216T3 (es) * 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2099764B1 (en) * 2006-09-20 2011-07-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
AU2007313103C1 (en) 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
AU2012216358B2 (en) * 2006-10-17 2014-11-20 Penick Corporation Process For Preparing Oxymorphone, Naltrexone and Buprenorphine
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
ES2393221T3 (es) * 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
WO2008070656A2 (en) * 2006-12-04 2008-06-12 Noramco, Inc Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
EP2137189B1 (en) * 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
ES2438997T5 (es) * 2007-03-23 2024-09-03 SpecGx LLC Preparación mejorada de oximorfona a partir de oripavina
CA2684458A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
US20090018154A1 (en) * 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009079013A1 (en) * 2007-12-17 2009-06-25 Mallinckrodt Inc. Processes for the production of (+)-'nal' morphinan compounds
US8461337B2 (en) 2007-12-17 2013-06-11 Mallinckrodt Llc Sinomenine derivatives and processes for their synthesis
EP2319845B1 (en) 2008-02-29 2013-07-24 Mallinckrodt LLC 3-Hydroxymorphinan derivatives
CA2722246C (en) * 2008-04-24 2016-06-21 Janssen Pharmaceutica Nv Nalmefene prodrugs
US8148528B2 (en) * 2008-05-27 2012-04-03 Mallinckrodt Llc Processes and compounds for the preparation of normorphinans
EP2331508B1 (en) 2008-09-03 2014-11-12 Mallinckrodt LLC Substituted berbines and processes for their synthesis
CA2738246C (en) * 2008-09-30 2017-09-05 Mallinckrodt Inc. Processes for the alkylation of secondary amine groups of morphinan derivatives
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
CA2802294C (en) 2010-06-11 2016-05-10 Rhodes Technologies Process for n-dealkylation of tertiary amines
PL2588481T3 (pl) 2010-07-02 2018-05-30 Johnson Matthey Public Limited Company Sposób syntezy i oczyszczania oksykodonu
RU2448709C1 (ru) * 2011-02-01 2012-04-27 Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) Способ получения налтрексона
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
ES2623262T3 (es) 2012-12-14 2017-07-10 Purdue Pharma Lp Derivados de morfinano que contienen nitrógeno y el uso de los mismos
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
AU2013369037C1 (en) 2012-12-31 2017-06-08 Rhodes Technologies Process for preparing 7beta-substituted 6alpha,14alpha -ethenomorphinans and 7beta-substituted 6alpha,14alpha-ethanomorphinans
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
EP2829541A1 (en) 2013-07-26 2015-01-28 Siegfried AG Novel synthesis of noroxymorphone from morphine
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
RU2683317C2 (ru) * 2014-11-25 2019-03-28 Кемфарм, Инк. Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой
EP3252055B1 (en) 2016-05-31 2018-09-19 Alcaliber Investigacion Desarrollo e Innovacion SLU Process for obtaining 3,14-diacetyloxymorphone from oripavine
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
SK592017A3 (sk) 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
AU2019224127B2 (en) 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof
CN110054656B (zh) * 2019-05-28 2021-02-02 宜昌人福药业有限责任公司 一种10-羰基/羟基吗啡-6-葡萄糖苷酸的合成方法
EP3997092A4 (en) * 2019-07-08 2023-09-06 University of Health Sciences & Pharmacy in St. Louis G-PROTEIN INFLUENCED OPIOID RECEPTOR AGONIST/ANALGESICS WITH REDUCED ARRESTIN RECRUITMENT
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CN114621239B (zh) * 2020-12-10 2026-02-03 鲁南制药集团股份有限公司 一种纳曲酮的制备方法
AU2021416361A1 (en) * 2020-12-28 2023-06-08 Navin Saxena Research & Technology Pvt. Ltd. Novel process for the synthesis of noroxymorphone from morphine
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819636A (en) * 1970-09-15 1974-06-25 American Home Prod 4a,10-(methaniminomethano)phenanthrene derivatives
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) * 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) * 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
IT1199871B (it) * 1984-03-27 1989-01-05 Mallinckrodt Inc Procedimento per la preparazione di norossimorfone dalla morfina e composti intermedi per tale procedimento
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4912114A (en) * 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives

Also Published As

Publication number Publication date
TR200000033T2 (tr) 2000-12-21
TW505648B (en) 2002-10-11
CN1272845A (zh) 2000-11-08
US6013796A (en) 2000-01-11
JP2001518444A (ja) 2001-10-16
HK1028025A1 (en) 2001-02-02
RU2183636C2 (ru) 2002-06-20
EP1000065B1 (en) 2005-03-16
CA2296035C (en) 2004-04-13
US5948788A (en) 1999-09-07
KR20010021693A (ko) 2001-03-15
ATE291023T1 (de) 2005-04-15
HUP0003918A2 (hu) 2001-07-30
CA2296035A1 (en) 1999-01-21
SK102000A3 (en) 2000-07-11
ZA986144B (en) 1999-05-19
EP1000065A1 (en) 2000-05-17
AU8379198A (en) 1999-02-08
AU740822B2 (en) 2001-11-15
KR100363486B1 (ko) 2002-12-16
IL133792A0 (en) 2001-04-30
NO20000111D0 (no) 2000-01-10
EP1000065A4 (en) 2001-09-12
DE69829379D1 (de) 2005-04-21
NO20000111L (no) 2000-02-25
US5952495A (en) 1999-09-14
IN1998KO01500A (https=) 2005-03-11
US6008355A (en) 1999-12-28
HUP0003918A3 (en) 2003-04-28
US5922876A (en) 1999-07-13
WO1999002529A1 (en) 1999-01-21
US5869669A (en) 1999-02-09
US6008354A (en) 1999-12-28

Similar Documents

Publication Publication Date Title
CN1152880C (zh) 羟氢吗啡酮、羟氢可待酮及其衍生物的制备方法
CN1037439C (zh) 制备具有神经保护作用的吲哚酮及有关衍生物的方法
US5244904A (en) Indole derivatives
CN1665819A (zh) 吗啡喃衍生物及其14位取代季铵盐、制备方法和它们的用途
CN1688544A (zh) 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
JP2001518444A5 (https=)
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1258533C (zh) 抗组胺的螺环化合物
CN1226825A (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1144787C (zh) 芳基稠合氮杂多元环化合物
CN101068782A (zh) 合成4－(3－磺酰基苯基)－哌啶类的方法
CN1083453C (zh) 作为多种药剂抗性调节剂的稠合的咪唑衍生物
CN1918168A (zh) 制备3－o－保护吗啡酮和3－o－保护吗啡酮二烯醇羧酸酯的方法
CN1281607C (zh) 具有镇痛作用的新型单哌嗪季铵盐类化合物
CN1117754C (zh) 吲哚并吗啡喃衍生物及其组合物
CN1900076A (zh) 四氢原小檗碱类化合物及其制备方法和用途
CN1486321A (zh) 吲哚衍生物及其医药应用
CN1126995A (zh) 抗过敏咪唑并吖庚因
HK1046144A1 (zh) 取代的苯并内酰胺化合物
CN1942473A (zh) 生产五环紫杉烷的方法
RU2272037C9 (ru) Способ получения 3-{2-[4-(6-фторбензо[d]изоксазол-3-ил)пиперидин-1-ил]этил}-2-метил-6,7,8,9-тетрагидро-4н-пиридо[1,2-а]пиримидин-4-она, промежуточные производные для его получения и способ получения промежуточного производного
CN86108415A (zh) 新型异吲哚满衍生物及其制备方法
CN1319093A (zh) 作为no合成酶抑制剂的氨基烷基－3,4－二氢喹啉衍生物
CN87102944A (zh) 新麦角烯(Ergolene)衍生物、其药物组合物及其制备方法
JP2000515534A (ja) ３，３―二置換ピペリジンの製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee